BioArctic Past Earnings Performance
Past criteria checks 3/6
BioArctic's earnings have been declining at an average annual rate of -18.4%, while the Biotechs industry saw earnings growing at 17.7% annually. Revenues have been declining at an average rate of 9.6% per year. BioArctic's return on equity is 21.9%, and it has net margins of 37.2%.
Key information
-18.4%
Earnings growth rate
-18.3%
EPS growth rate
| Biotechs Industry Growth | 11.5% |
| Revenue growth rate | -9.6% |
| Return on equity | 21.9% |
| Net Margin | 37.2% |
| Next Earnings Update | 17 May 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How BioArctic makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 616 | 229 | 251 | 0 |
| 30 Sep 23 | 611 | 259 | 236 | 0 |
| 30 Jun 23 | 620 | 270 | 230 | 0 |
| 31 Mar 23 | 622 | 327 | 178 | 0 |
| 31 Dec 22 | 229 | -11 | 149 | 0 |
| 30 Sep 22 | 232 | 28 | 131 | 0 |
| 30 Jun 22 | 18 | -147 | 110 | 0 |
| 31 Mar 22 | 21 | -135 | 104 | 0 |
| 31 Dec 21 | 26 | -120 | 97 | 0 |
| 30 Sep 21 | 30 | -114 | 95 | 0 |
| 30 Jun 21 | 37 | -97 | 89 | 0 |
| 31 Mar 21 | 34 | -101 | 87 | 0 |
| 31 Dec 20 | 65 | -69 | 86 | 0 |
| 30 Sep 20 | 84 | -72 | 87 | 0 |
| 30 Jun 20 | 93 | -60 | 87 | 0 |
| 31 Mar 20 | 252 | 78 | 94 | 0 |
| 31 Dec 19 | 283 | 88 | 91 | 0 |
| 30 Sep 19 | 779 | 441 | 101 | 0 |
| 30 Jun 19 | 852 | 475 | 101 | 0 |
| 31 Mar 19 | 729 | 380 | 91 | 0 |
| 31 Dec 18 | 722 | 382 | 89 | 0 |
| 30 Sep 18 | 257 | 58 | 78 | 0 |
| 30 Jun 18 | 197 | 32 | 77 | 0 |
| 31 Mar 18 | 194 | 29 | 83 | -17 |
| 31 Dec 17 | 157 | 15 | 69 | 0 |
| 30 Sep 17 | 193 | 78 | 54 | 22 |
| 30 Jun 17 | 160 | 71 | 41 | 31 |
| 31 Mar 17 | 127 | 64 | 17 | 60 |
| 31 Dec 16 | 106 | 58 | 16 | 54 |
| 31 Dec 15 | 42 | 4 | 6 | 38 |
Quality Earnings: 0RV2 has high quality earnings.
Growing Profit Margin: 0RV2 became profitable in the past.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 0RV2's earnings have declined by 18.4% per year over the past 5 years.
Accelerating Growth: 0RV2 has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: 0RV2 has become profitable in the last year, making it difficult to compare its past year earnings growth to the Biotechs industry (-11.5%).
Return on Equity
High ROE: 0RV2's Return on Equity (21.9%) is considered high.